{"news_desk": "National", "print_page": "13", "subsection_name": null, "section_name": "Health", "byline": {"original": "By GINA KOLATA", "person": [{"firstname": "Gina", "rank": 1, "lastname": "KOLATA", "organization": "", "role": "reported"}]}, "abstract": "Results of two large clinical trials of drug dupilumab, developed to treat uncontrolled, moderate-to-severe atopic dermatitis, type of eczema, are published in New England Journal of Medicine; trials show promising results, with some patients experiencing instantaneous relief from itching that can sometimes be so unbearable patients consider suicide.", "type_of_material": "News", "word_count": "1201", "keywords": [{"rank": "1", "value": "Eczema", "is_major": "Y", "name": "subject"}, {"rank": "2", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "name": "subject"}, {"rank": "3", "value": "Food and Drug Administration", "is_major": "N", "name": "organizations"}, {"rank": "5", "value": "Sanofi SA", "is_major": "N", "name": "organizations"}, {"rank": "6", "value": "Regeneron Pharmaceuticals Inc", "is_major": "N", "name": "organizations"}, {"rank": "7", "value": "New England Journal of Medicine", "is_major": "Y", "name": "organizations"}, {"rank": "8", "value": "Research", "is_major": "N", "name": "subject"}], "lead_paragraph": "Atopic dermatitis causes itching so extreme that many patients consider suicide. In trials, most patients said symptoms waned in the first two weeks of taking a new drug.", "pub_date": "2016-10-01T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "Atopic dermatitis causes itching so extreme that many patients consider suicide. In trials, most patients said symptoms waned in the first two weeks of taking a new drug....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/10/01/science/01SKIN/01SKIN-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/10/01/science/01SKIN/01SKIN-thumbWide.jpg"}, {"height": 438, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "438", "xlarge": "images/2016/10/01/science/01SKIN2/01SKIN2-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/10/01/science/01SKIN2/01SKIN2-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/10/01/science/01SKIN/01SKIN-thumbStandard-v2.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/10/01/science/01SKIN/01SKIN-thumbStandard-v2.jpg"}], "web_url": "http://www.nytimes.com/2016/10/01/health/severe-eczema-atopic-dermatitis-drug.html", "slideshow_credits": null, "blog": [], "_id": "57ef510095d0e021d79897e7", "headline": {"main": "New Drug for Severe Eczema Is Successful in 2 New Trials", "print_headline": "2 Trials Show New Treatment for Severe Eczema Can Provide Swift Relief"}}